Oncotelic Therapeutics, Inc. (OTLC) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Agoura Hills, CA, United States. The current CEO is Vuong Trieu.
OTLC has IPO date of 1993-08-26, 26 full-time employees, listed on the Other OTC, a market capitalization of $16.02M.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
